NVXCoV 2373
Alternative Names: Coronavirus vaccine - Novavax; COVID-19 vaccine - Novavax; COVOVAX; Covovax; Nuvaxovid; NVX-CoV-2373; NVX-CoV2601; NVX-CoV2705; NVX‑CoV2373 vaccine; Recombinant spike protein of SARS-CoV-2 virus vaccine; SARS-CoV-2 recombinant spike protein nanoparticle vaccine; SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine - Novavax; SARS-CoV-2 rS nanoparticle vaccine; TAK-019Latest Information Update: 03 Sep 2024
At a glance
- Originator Novavax
- Developer Novavax; Serum Institute of India; Takeda
- Class Adjuvants; COVID-19 vaccines; Protein vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed COVID 2019 infections
Most Recent Events
- 30 Aug 2024 The US Food and Drug Administration (US FDA) approves an emergency use authorization (EUA) for NVX-CoV2705 for COVID-2019 infections (Prevention, In adolescents, In adults, In the elderly) in USA
- 08 Aug 2024 US FDA assigns PDUFA action date of April 2025 for NVXCoV-2373 for COVID-2019 infections
- 08 Aug 2024 US FDA accepts BLA for NVXCoV 2373 for COVID-2019 infections for review